作者：
Brown,C.K. [1]
;
Friedel,H.D. [2]
;
Barker,A.R. [3]
;
Buhse,L.F. [4]
;
Keitel,S. [5]
;
Cecil,T.L. [6]
;
Kraemer,J. [7]
;
MichaelMorris,J. [8]
;
Reppas,C. [9]
;
Stickelmeyer,M.P. [10]
;
Yomota,C. ;
Shah,V.P.
作者单位：
Irish Medicines Board, Dublin, Ireland
[1]
Eli Lilly and Company, Indianapolis, IN, United States
[2]
National and Kapodistrian University of Athens, Panepistimiopolis, Greece
[3]
National Institute of Health Science, Tokyo, Japan
[4]
EDQM, Council of Europe, Strasbourg, France
[5]
FIP Scientific Secretary, The Hague, Netherlands
[6]
Bayer HealthCare AG, Berlin, Germany
[7]
United States Pharmacopeia, Rockville, MD, United States
[8]
Food and Drug Administration/CDER/OPS, St. Louis, MO, United States
[9]
PHAST, Homburg, Germany
[10]
发布时间
2013-11-20
换一批
